Scancell and ISA Pharmaceuticals announce collaboration To download click here Thursday 15 February 2018 13:00 Categories: Modi-1 Moditope News Regulatory News Year - 2018
Scancell drug receives positive write-up in leading journal as company updates on survival data Immuno-therapy SCIB1, which is expected to progress into Phase II clinical trials in the second-half of the year, was the focus of a peer-reviewed paper in OncoImmunology [View article] Monday 12 February 2018 16:50 Categories: Media Coverage SCIB1 Year - 2018
Peer-reviewed publication highlights potential of SCIB1 therapy for melanoma patients To download click here Monday 12 February 2018 13:00 Categories: News Regulatory News SCIB1 Year - 2018
Moditope European Patent to be granted To download click here Friday 9 February 2018 13:00 Categories: Moditope News Regulatory News Year - 2018
Scancell to receive patent protection for key cancer platform Once formally granted, the patent will provide protection for Scancell’s pipeline of Moditope vaccines [View article] Friday 9 February 2018 12:30 Categories: Media Coverage Moditope Year - 2018
Scancell-led team short-listed for award The Cancer Research UK Grand Challenge is a prestigious award that brings with it significant funding [View article] Thursday 8 February 2018 13:00 Categories: Media Coverage Year - 2018
Scancell a member of team shortlisted for Cancer Research UK's Grand Challenge Award To download click here Thursday 8 February 2018 13:00 Categories: Modi-1 Moditope News Regulatory News Year - 2018
Announcement of Share Options 1 February 2018 To download click here Thursday 1 February 2018 13:00 Categories: News Regulatory News Year - 2018
Scancell eyeing investigational new drug application for SCIB1 in first half Patient enrolment for the SCIB1 Phase 2 checkpoint inhibitor combination study for patients with advanced melanoma is planned to start in the second half of the year [View article] Tuesday 30 January 2018 12:58 Categories: Media Coverage SCIB1 Year - 2018
Scancell poised for “significant” year with its immuno-oncology portfolio "In our view, the potential for SCIB1 [Scancell's skin cancer treatment], as already demonstrated by the survival data, is remarkable," said one broker recently [View article] Monday 15 January 2018 15:30 Categories: Media Coverage SCIB1 SCIB2 Year - 2018